Corbevax vax to cost Rs 990 in market, Rs 145 for govt
Biological E produced Corbevax vaccine shot for children between 12 to 14 age group will cost Rs 990 in the private market including all taxes and Rs 145 at government hospitals and facilities. India on Wednesday expanded its Covid-19 vaccination drive with the inclusion of children in the age group of 12-14. As per the health ministry report, children in this age group will be administered Corbevax vaccine manufactured by Hyderabad-based Biological E.
Vaccination for 12-14 years age group to begin Wednesday: Centre
The Covid-19 vaccination for all beneficiaries in the 12-14 age group will begin from Wednesday, National Vaccination Day, at all government Covid vaccination centres. The vaccine to be administered would be Corbevax, manufactured by Biological E. Limited, Hyderabad, said Rajesh Bhushan, Union Health Secretary, in a virtual meeting with all states and UTs on Tuesday.
Explained: India's first mRNA Covid vax
Pune-based Gennova Biopharmaceuticals is making India's first mRNA vaccine known as HGC019, in collaboration with US-based HDT Bio Corp. In August, the Drug Controller General of India had approved the Phase 2 and 3 clinical trials. "The Vaccine Subject Expert Committee (SEC) reviewed the data, and found HGCO19 to be safe, tolerable, and immunogenic in the participants of the study," the company had said in a statement.
India gears up to vaccinate teens from Monday
Union Health Minister Mansukh Mandaviya on Saturday tweeted: "On the occasion of New Year, registration is being started on CoWIN portal for immunisation of children against COVID-19 in the age group of 15 to 18 years from today. I request the family members to register the eligible children for vaccination".
Goat pox vaccine launched in India
'Raksha Goat Pox', of leading Indian Immunologicals Ltd (IIL), is a live attenuated vaccine I.P. (Uttarkashi strain) grown on vero cell culture. The primary vaccination has to be done at 3 months of age and re-vaccination annually. The technology for the vaccine and its testing was obtained from Indian Council of Agriculture Research-Indian Veterinary Research Institute (ICAR- IVRI), Government of India and has been tested and certified by it for commercial release.
WHO body seeks more clarification to decide on Covaxin EUL
The WHO's Technical Advisory Group in a meeting on Tuesday agreed upon to conduct the final risk assessment after receiving additional data from manufacturer. Hyderabad based Bharat Biotech is expected to submit the data by this weekend. The Technical Advisory Group may meet for the final risk-benefit assessment on November 3. The company also submitted additional info at WHO's request on September 27.
SII seeks regular marketing authorisation for Covishield from DCGI
The application sent to the DCGI said that SII has already submitted phase-3 clinical study results of 24,244 subjects from the UK, Brazil and South Africa to the Central Drugs Standard Control Organisation (CDSCO) in June. Apart from that the phase 3 clinical study results of 32,379 subjects from the US, Chile and Peru were submitted on July 9.
Don't cast doubt on vaccination: SC junks plea against mass vax of Covishield, Covaxin
Refusing to interfere in the matter, a bench comprising Justices D.Y. Chandrachud and B.V. Nagarathna told the petitioner's counsel, "We do not want this matter to be argued at all. Let us not cast doubt on the vaccination". The Counsel appearing for petitioner Mathew Thomas urged the bench to hear his arguments in the matter in detail. However, the bench responded that it was not keen on entertaining the plea.